Retinitis Pigmentosa clinical trials at UC Davis
2 research studies open to eligible people
Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
“We hope to learn more about the safety and feasibility of using your own (autologous) stem cells extracted from your bone marrow.”
open to eligible people ages 18-100
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
Sacramento, California
Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.
Sacramento, California
Our lead scientists for Retinitis Pigmentosa research studies include Susanna s Park, MD PhD.
Last updated: